FDA approves first generic versions of Zyprexa
October 24, 2011 in Medications
(AP) -- Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.
Zyprexa posted sales of $5.7 billion last year for drugmaker Eli Lilly & Co Inc., according to prescription tracking company IMS Health.
The new low-cost versions of the drug will be marketed by Indian generic drugmaker Dr. Reddy's Laboratories and by Teva Pharmaceutical Industries, based in Israel.
Zyprexa is part of a class of medications called atypical antipsychotics that effect levels of dopamine, a brain chemical that controls behavior, mood and movement. Doctors overwhelmingly embraced the drugs in the 1990s over older treatments, because they were thought to be less likely to cause side effects like muscle tremors and spasms. The newer medications have their own side effects; including weight gain, high blood sugar and drowsiness.
Drugs like Zyprexa can cost up to $500 per month. Generic versions can cut the cost by up to 80 percent.
FDA approves generic versions of medications after the patent on the original drug expires or has been ruled invalid in court.
Shares of Indianapolis-based Eli Lilly rose 12 cents to $38.19 in afternoon trading.
©2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
-
Mississippi sues pharmaceutical company
Jul 25, 2006 |
not rated yet |
0
-
Mississippi sues pharmaceutical company
Jul 25, 2006 |
not rated yet |
0
-
FDA panel backs 3 psychiatric drugs for kids
Jun 11, 2009 |
not rated yet |
0
-
Lilly, Boehringer collaborate on diabetes drugs
Jan 11, 2011 |
not rated yet |
0
-
FDA weighs approval of psychiatric drugs for kids
Jun 05, 2009 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Breakup of physician, drug company relationship could improve health care, cut cost
A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...
Medications
1 hour ago |
not rated yet |
0
FDA has safety concerns on Merck insomnia drug
Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.
Medications
2 hours ago |
not rated yet |
0
US adviser on board of firm that sold anthrax drug
(AP)—Former Navy Secretary Richard J. Danzig, who has served as a bio-warfare adviser to the president, the Pentagon, and the Department of Homeland Security, urged the government to stockpile an anti-anthrax drug while ...
Medications
8 hours ago |
5 / 5 (1) |
0
Acne pill benefits outweigh blood clot risk: EU agency
Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.
Medications
May 17, 2013 |
not rated yet |
0
First influenza vaccine brought to clinical testing
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...
Medications
May 17, 2013 |
5 / 5 (1) |
0
Digital divide exists with physician EHR adoption
(HealthDay)—The majority of physicians remain reluctant to adopt health information technology (HIT), according to a report by Deloitte Touche Tohmatsu.
One in ten teens using 'study drugs,' but parents aren't paying attention
As high schoolers prepare for final exams, teens nationwide may be tempted to use a "study drug"—a prescription stimulant or amphetamine—to gain an academic edge. But a new University of Michigan poll shows only one in ...
Food laboratory accuracy remains a concern
Food microbiology laboratories continue to submit false negative results and false positive results on a routine basis. A retrospective study of nearly 40,000 proficiency test results over the past 14 years, presented today ...
Study supports 'aggressive' treatment for posterior fossa hematoma in newborns
Posterior fossa subdural hematoma (PFSDH) is a serious and rare condition in newborns, generally occurring after difficult deliveries. But with appropriate treatment, there's an excellent chance of good long-term outcomes ...
Hospital emergency departments gaining in importance, study finds
Hospital emergency departments play a growing role in the U.S. health care system, accounting for a rising proportion of hospital admissions and serving increasingly as an advanced diagnostic center for primary care physicians, ...
Neurons that can multitask greatly enhance the brain's computational power, study finds
Over the past few decades, neuroscientists have made much progress in mapping the brain by deciphering the functions of individual neurons that perform very specific tasks, such as recognizing the location ...
